Publications - 'A'

Publications 926 - 950 de 3773
| % | ( | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | < | ? | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | [ | ` | {
Titre DOI
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial
G. Olivier; A. Clavert; L. Lacotte-Thierry; M. Gardembas; M. Escoffre-Barbe; A. Brion; I. Cumin; E. Legouffe; P. Solal-Celigny; M. Chabin; P. Ingrand; P. Colombat; V. Delwail
2014 		10.1002/ajh.23812
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
R.S. Herbst; J.C. Bendell; N. Isambert; E. Calvo; R. Santana-Davila; P. Cassier; J.Luis Perez-Gracia; J. Yang; J. Rege; D. Ferry; G. Mi; I. Chau
2016 		10.1200/JCO.2016.34.15_suppl.3056
A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study
Q. Jacquinot; N. Meneveau; M. Chatot; F. Bonnetain; B. Degano; M. Bouhaddi; G. Dumoulin; D. Vernerey; X. Pivot; F. Mougin
2017 		10.1186/s12885-017-3420-4
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (MBC)
G. Curigliano; S. Loibl; V. Mueller; X. Pivot; A. Wardley; D. Cameron
2016 		10.1093/annonc/mdw365.91
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
R. Gressin; N. Daguindau; A. Tempescul; A. Moreau; S. Carras; E. Tchernonog; A. Schmitt; R. Houot; C. Dartigeas; J.Michel Pignon; S. Corm; A. Banos; C. Mounier; J. Dupuis; M. Macro; J. Fleury; F. Jardin; C. Sarkozy; G. Damaj; P. Feugier; L.Matthieu Fornecker; C. Chabrot; V. Dorvaux; K. Bouadallah; S. Amorin; R. Garidi; L. Voillat; B. Joly; P.Solal Celigny; N. Morineau; M.Pierre Moles; H. Zerazhi; J. Fontan; Y. Arkam; M. Alexis; V. Delwail; J.Pierre Vilque; L. Ysebaert; S. Le Gouill; M.B. Callanan; L.Study Assoc
2019 		10.3324/haematol.2018.191429
A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
N. Kalakonda; F. Cavallo; G. Follows; A. Goy; J.S.P. Vermaat; O. Casasnovas; O. Lavee; M. Maerevoet; J. Zijlstra; S. Bakhshi; R. Bouabdallah; S. Choquet; R. Gurion; B. Hill; U. Jaeger; J.M. Sancho; M. Schuster; C. Thieblemont; F. De la Cruz; M. Egyed; S. Mishra; F. Offner; T. Vassilakopoulos; K. Warzocha; D. McCarthy; X. Ma; K. Corona; J.R. Saint-Martin; A. Joshi; J. Shah; E. Van Den Neste; M. Canales
2019 		10.1016/j.clml.2019.07.153
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
K. Fizazi; X. Maldonado; S. Foulon; G. Roubaud; R.S. McDermott; A. Flechon; B.F. Tombal; S. Supiot; D.R. Berthold; P. Ronchin; G. Kacso; G. Gravis; F. Calabro; J.Francois Berdah; A. Hasbini; M. Silva; A. Thiery-Vuillemin; I. Rieger; M.Laure Tanguy; A. Bossi
2021 		10.1200/JCO.2021.39.15_suppl.5000
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma
G. Truc; V. Bernier; C. Mirjolet; C. Dalban; F. Mazoyer; F. Bonnetain; N. Blanchard; E. Lagneau; P. Maingon; G. Noel
2016 		10.1016/j.canrad.2015.12.005
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)
P. Fumoleau; K.M. Koch; E. Brain; F. Lokiec; K. Rezai; A. Awada; L. Hayward; G. Werutsky; J. Bogaerts; S. Marreaud; F. Cardoso
2014 		10.1016/j.breast.2014.07.003
A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee)
B. Nelken; H. Cave; G. Leverger; C. Galambrun; G. Plat; C. Schmitt; C. Thomas; C. Verite; B. Brethon; V. Gandemer; Y. Bertrand; A. Baruchel; P. Rohrlich
2016 		10.1002/pbc.25751
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
V. Dieras; T. Bachelot; M. Campone; N. Isambert; F. Joly; C. Le Tourneau; P. Cassier; E. Bompas; P. Fumoleau; S. Noal; C. Orsini; M. Jimenez; D.Charlotte Imbs; E. Chatelut
2016 		10.1007/s40487-016-0027-x
A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
N. Isambert; E. Elez; S. Zanetta; I. Matos; S. Nazabadioko; W. Xue; P. Carriere; J. Tabernero
2018 		10.1200/JCO.2018.36.15_suppl.e24013
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
N.Guastad Daver; P. Montesinos; D.J. DeAngelo; E.S. Wang; E. Todisco; C. Tarella; G. Martinelli; H.Paul Erba; E. Deconinck; K.L. Sweet; R.B. Walter; M.Yair Levy; N. Pemmaraju; A.A. Lane; D. Rizzieri; M. Konopleva; C.Mortimer Sloss; J. Wang; K.E. Malcolm; P.A. Zweidler-McKay
2020
A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
N.Guastad Daver; P. Montesinos; D.J. DeAngelo; E.S. Wang; E. Todisco; C. Tarella; G. Martinelli; H.Paul Erba; E. Deconinck; K.L. Sweet; R.B. Walter; M.Yair Levy; N. Pemmaraju; A.A. Lane; D. Rizzieri; M. Konopleva; C.Mortimer Sloss; J. Wang; K.E. Malcolm; P.A. Zweidler-McKay
2020
A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy
F. Morschhauser; G.Andre Salles; R.O. Casasnovas; P. Feugier; K. Bouabdallah; G. Cartron; R. Bouabdallah; E. Nicolas-Virelizier; M. Maerevoet; S. Snauwaert; C. Fruchart; S.L.E. Gouill; C. Molucon-Chabrot; C. Delette; L. Molina; H. Tilly; C. Thieblemont; E. Van Den Neste; F. Bijou; B. Fabiani; C. Haioun; R. Houot
2018 		10.1182/blood-2018-99-112805
A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma
F. Morschhauser; G. Cartron; G.A. Salles; F. Bijou; C. Fruchart; K. Bouabdallah; P. Feugier; S. Le Gouill; H. Tilly; C. Molucon-Chabrot; M. Maerevoet; R.O. Casasnovas; E.W. Van den Neste; P. Zachee; K. Van Eygen; A. Van Hoof; C. Bonnet; C. Haioun; M. Andre; L. Xerri; R. Houot
2016 		10.1182/blood.V128.22.4202.4202
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P. Pautier; N. Penel; I. Ray-Coquard; A. Italiano; E. Bompas; C. Delcambre; J.O. Bay; F. Bertucci; J. Delaye; C. Chevreau; D. Cupissol; L. Bozec; J.C. Eymard; E. Saada; N. Isambert; C. Guillemet; M. Rios; S. Piperno-Neumann; G. Chenuc; F. Duffaud
2020 		10.1016/j.ejca.2019.10.028
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 ``PembroRad'' trial.
X.Shan Sun; C. Sire; Y. Tao; L. Martin; M. Alfonsi; J.Briac Prevost; M. Rives; C. Lafond; J.M. Tourani; J. Biau; L. Geoffrois; A. Coutte; X. Liem; E. Vauleon; F. Drouet; J.F. Ramee; G. Waksi; L. Sinigaglia; A. Auperin; J. Bourhis
2018 		10.1200/JCO.2018.36.15_suppl.6018
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma
F. Selle; E. Sevin; I. Ray-Coquard; V. Mari; D. Berton-Rigaud; L. Favier; M. Fabbro; A. Lesoin; A. Lortholary; E. Pujade-Lauraine
2014 		10.1093/annonc/mdu392
A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
R. Galot; C. Le Tourneau; E. Saada-Bouzid; A. Daste; C. Even; P.R. Debruyne; S. Henry; S. Zanetta; A. Rutten; L.F. Licitra; J.L. Canon; M.C. Kaminsky-Forrett; P. Specenier; S. Rottey; L. Dirix; T. Raveloarivahy; F. Lefevre; M.B.M. Vanlancker; A.S. Govaerts; J.P. Machiels
2019
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
E. Van Den Neste; M. Andre; T. Gastinne; A. Stamatoullas; C. Haioun; A. Belhabri; O. Reman; O. Casasnovas; H. Ghesquieres; G. Verhoef; M.J. Claessen; H.A. Poirel; M.C. Copin; R. Dubois; P. Vandenberghe; I.A. Stoian; A.S. Cottereau; S. Bailly; L. Knoops; F. Morschhauser
2018 		10.3324/haematol.2017.180554
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
H. Bonnefoi; T. Grellety; O. Tredan; M. Saghatchian; F. Dalenc; A. Mailliez; T. L'Haridon; P. Cottu; S. Abadie-Lacourtoisie; B. You; M. Mousseau; J. Dauba; F. Del Piano; I. Desmoulins; F. Coussy; N. Madranges; J. Grenier; F.C. Bidard; C. Proudhon; G. MacGrogan; C. Orsini; M. Pulido; A. Goncalves
2016 		10.1093/annonc/mdw067
A phase II trial of sorafenib (SO) in advanced chordoma patients (pt)
E. Amela; E. Bompas; A. Le Cesne; E. Tresch; A. Italiano; S. Piperno-Neumann; O. Collard; D. Vansteene; J. Domont; E. Saada; N. Isambert; S. Salas; C. Chevreau; F. Bertucci; S.Clisant Delaine; J.Y. Blay; N. Penel
2015
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
B. Coiffier; C. Thieblemont; S. de Guibert; J. Dupuis; V. Ribrag; R. Bouabdallah; F. Morschhauser; R. Navarro; S. Le Gouill; C. Haioun; R. Houot; O. Casasnovas; H. Holte; T. Lamy; F. Broussais; S. Payrard; L. Hatteville; H. Tilly
2016 		10.1111/bjh.13992
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
B. Bui-Nguyen; J.E. Butrynski; N. Penel; J.Y. Blay; N. Isambert; M. Milhem; J.M. Kerst; A.K.L. Reyners; S. Litiere; S. Marreaud; F. Collin; W.T.A. van der Graaf; E.O.R.T.C. STBSG; SARC
2015 		10.1016/j.ejca.2015.03.023

Pages